DexCom's stock fell sharply after mixed Q2 earnings and lowering full-year guidance, signaling a revaluation phase with lower ...

DexCom experienced slower growth and profitability challenges, but still met management's expectations for the quarter.

Q3 2024 Earnings Call Transcript October 24, 2024 DexCom, Inc. beats earnings expectations. Reported EPS is $0.45, ...

Operator Ladies and gentlemen, welcome to the Dexcom third quarter 2024 earnings release conference call. My name is Abby, ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Despite a dip in US revenue, DexCom Inc (DXCM) sees promising international growth and strategic product launches.

In the two months that Stelo has been available, Dexcom is seeing a mix of people using the device. Many users are diabetic patients who don’t qualify for insurance coverage of a CGM ...

Dexcom selected Athenry, Co Galway, as the site for its state-of-the-art global continuous glucose monitoring manufacturing facility The west of Ireland received a massive boost in 2023 when medtech ...

Dexcom stock drops 40% after reporting CGM sales challenges Earlier this year, Dexcom’s stock dropped about 40% after it disclosed commercialization setbacks and reduced its annual revenue ...

I really did.” DexCom (NASDAQ:DXCM) designs, develops, and commercializes continuous glucose monitoring (CGM) systems aimed at improving diabetes management. Among its flagship products are the ...

In the competitive landscape, Abbott launched its over-the-counter continuous glucose monitoring system, Lingo, rivaling a similar device by DexCom. Canaccord Genuity maintained its positive ...